{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:16:07Z","timestamp":1778897767385,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016300","name":"Octapharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rpth.2025.103277","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:19:10Z","timestamp":1764692350000},"page":"103277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of a factor VIII\/immunoglobulin heavy chain \u03bc double-knockout mouse model of hemophilia A for long-term exposure to factor VIII proteins"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2325-6540","authenticated-orcid":false,"given":"Lara","family":"Monica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Oleshko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Aires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Wuschko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"F\u00fcner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Schauerte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ditte Starberg","family":"Jespersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Belyanskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Tiede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Werwitzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103277_bib1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/312326a0","article-title":"Characterization of the human factor VIII gene","volume":"312","author":"Gitschier","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.rpth.2025.103277_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1160\/TH10-07-0492","article-title":"High incidence of ankle arthropathy in mild and moderate haemophilia A","volume":"105","author":"Ling","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103277_bib3","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2022007620","article-title":"The bleeding phenotype in people with nonsevere hemophilia","volume":"6","author":"Kloosterman","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103277_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.blre.2018.05.002","article-title":"Increased bone resorption in hemophilia","volume":"33","author":"Rodriguez-Merchan","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2025.103277_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/hae.15013","article-title":"Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients","volume":"30","author":"Arvanitakis","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103277_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/hae.13616","article-title":"Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: the THUNDER study","volume":"25","author":"Scott","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103277_bib7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B","volume":"190","author":"Rayment","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.103277_bib8","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103277_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2125.2010.03899.x","article-title":"Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice","volume":"72","author":"Franchini","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2025.103277_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/asheducation-2016.1.657","article-title":"Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches","volume":"2016","author":"Meeks","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2025.103277_bib11","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2025.103277_bib12","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103277_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103277_bib14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/hae.13820","article-title":"Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas","volume":"25","author":"Patel-Hett","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103277_bib15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2025.103277_bib16","first-page":"2041","article-title":"Hemostasis and endothelial functionality: the double face of coagulation factors","volume":"109","author":"Olgasi","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2025.103277_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/hae.13986","article-title":"Biomarkers of bone disease in persons with haemophilia","volume":"27","author":"Goldscheitter","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103277_bib18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2516.2008.01963.x","article-title":"Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia","volume":"15","author":"Gerstner","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103277_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12959-016-0106-0","article-title":"Current animal models of hemophilia: the state of the art","volume":"14","author":"Yen","year":"2016","journal-title":"Thromb J"},{"key":"10.1016\/j.rpth.2025.103277_bib20","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1182\/blood.V88.9.3446.bloodjournal8893446","article-title":"Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies","volume":"88","author":"Bi","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103277_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.rpth.2025.103277_bib22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/jth.14013","article-title":"Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model","volume":"16","author":"Rode","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103277_bib23","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1365-2516.2012.02780.x","article-title":"A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(\u00ae))","volume":"18","author":"Pastoft","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103277_bib24","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.2020006468","article-title":"Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice","volume":"137","author":"Vollack-Hesse","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103277_bib25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1055\/s-0037-1614124","article-title":"Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A","volume":"84","author":"Reipert","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103277_bib26","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1055\/s-0037-1613094","article-title":"Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII","volume":"87","author":"Hausl","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103277_bib27","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1160\/TH14-06-0535","article-title":"Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro","volume":"114","author":"Werwitzke","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103277_bib28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/aps.2015.121","article-title":"Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice","volume":"37","author":"Gu","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.rpth.2025.103277_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/bdd.1880","article-title":"Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice","volume":"35","author":"Kosloski","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.rpth.2025.103277_bib30","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1038\/s41467-024-51296-8","article-title":"Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male mice","volume":"15","author":"Sternberg","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.rpth.2025.103277_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.V99.2.457","article-title":"Use of blood outgrowth endothelial cells for gene therapy for hemophilia A","volume":"99","author":"Lin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103277_bib32","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1634\/stemcells.2006-0699","article-title":"Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors","volume":"25","author":"Matsui","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.rpth.2025.103277_bib33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/350423a0","article-title":"A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene","volume":"350","author":"Kitamura","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.rpth.2025.103277_bib34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1084\/jem.182.4.915","article-title":"Successful T cell priming in B cell-deficient mice","volume":"182","author":"Epstein","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.rpth.2025.103277_bib35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.thromres.2012.09.011","article-title":"Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII","volume":"131","author":"Kannicht","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.103277_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1258\/la.2008.008057","article-title":"DNA analysis from stool samples: a fast and reliable method avoiding invasive sampling methods in mouse models of bleeding disorders","volume":"43","author":"Kalippke","year":"2009","journal-title":"Lab Anim"},{"key":"10.1016\/j.rpth.2025.103277_bib37","article-title":"Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol"},{"key":"10.1016\/j.rpth.2025.103277_bib39","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/cyto.a.24509","article-title":"OMIP-079: Cell cycle of CD4+ and CD8+ na\u00efve\/memory T cell subsets, and of Treg cells from mouse spleen","volume":"99","author":"Natalini","year":"2021","journal-title":"Cytometry A"},{"key":"10.1016\/j.rpth.2025.103277_bib40","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1160\/TH17-03-0201","article-title":"CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitro","volume":"117","author":"Vollack","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103277_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2003-07-2456","article-title":"Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders","volume":"104","author":"Hausl","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103277_bib42","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103277_bib43","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.4049\/jimmunol.0802501","article-title":"Requirement of B cells for generating CD4+ T cell memory","volume":"182","author":"Whitmire","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.rpth.2025.103277_bib44","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/jth.15741","article-title":"Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII","volume":"20","author":"Demers","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103277_bib45","first-page":"457","article-title":"Non-factor replacement therapy for haemophilia: a current update","volume":"16","author":"Franchini","year":"2018","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2025.103277_bib46","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"Gualtierotti","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103277_bib47","first-page":"206","article-title":"Ankle hemophilic arthropathy: literature review","volume":"11","author":"Greco","year":"2021","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.rpth.2025.103277_bib48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/jcm13010225","article-title":"Blood-induced arthropathy: a major disabling complication of haemophilia","volume":"13","author":"Leuci","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2025.103277_bib49","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1182\/blood-2006-07-037994","article-title":"B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo","volume":"109","author":"Li","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103277_bib50","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A hemophilia A mouse model for the in vivo assessment of emicizumab function","volume":"136","author":"Ferri\u00e8re","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103277_bib51","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4049\/jimmunol.161.3.1439","article-title":"Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection","volume":"161","author":"Yang","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.rpth.2025.103277_bib52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0165-5728(98)00238-0","article-title":"B cell-deficient mice have increased susceptibility to HSV-1 encephalomyelitis and mortality","volume":"94","author":"Beland","year":"1999","journal-title":"J Neuroimmunol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:54:57Z","timestamp":1778896497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925006016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2475037925006016"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103277","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of a factor VIII\/immunoglobulin heavy chain \u03bc double-knockout mouse model of hemophilia A for long-term exposure to factor VIII proteins","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103277"}}